Article Figures & Data
Figures
- FIGURE 1.
Enrollment flowchart.
- FIGURE 2.
Percentage of patients with reduction in pain, swelling, and joint effusion at 3, 6, and 12 mo after radiosynoviorthesis. Upper brackets indicate 95% CI. Number of evaluable patients is 225 at 3 mo, 211 at 6 mo, and 188 at 12 mo for pain; 229 at 3 mo, 213 at 6 mo, and 189 at 12 mo for swelling; and 207 at 3 mo, 200 at 6 mo, and 178 at 12 mo for joint effusion. *Significant improvement in synovitis symptoms compared with baseline (P < 0.001).
- FIGURE 3.
Improvement in patient’s functional disability based on HAQ-DI at baseline and during follow-up (3, 6, and 12 mo). Data are mean; brackets represent SD. Nonsignificant reduction in patient’s functional disability was observed at follow-up compared with baseline (P = 0.3). Smallest clinically significant difference in HAQ-DI is 0.25. Number of evaluable patients is 360 at baseline, 325 at 3 mo, 303 at 6 mo, and 251 at 12 mo. *Probability of HAQ-DI improvement decreases statistically significantly at 6 and 12 mo (P < 0.01).
- FIGURE 4.
Decrease in disease activity based on DAS28 at baseline and during follow-up (3, 6, and 12 mo). Data are mean; brackets represent SD. No significant reduction in disease activity was observed at follow-up compared with baseline (P = 0.1). Smallest clinically significant difference in DAS28 is 1.2. Number of evaluable patients is 299 at baseline, 265 at 3 mo, 240 at 6 mo, and 200 at 12 mo.
- FIGURE 5.
Stability of patient’s global assessment of disease activity based on VAS at baseline and during follow-up (3, 6, and 12 mo). Data are mean; brackets represent SD. No significant change in patient’s global assessment of disease activity was observed at follow-up compared with baseline (P = 0.5). Smallest clinically significant difference in VAS 100 mm is reduction of 20 mm. Number of evaluable patients is 286 at baseline, 255 at 3 mo, 238 at 6 mo, and 202 at 12 mo.
Tables
Characteristic Data Age (y) Mean 50.5 (SD, 16.9) Median 51.0 (range, 5.0–87.0) Sex Female 185 (51.4%) Male 173 (48.1%) Unknown 2 (0.5%) Joint inflammatory disease Spondyloarthropathies 110 (30.6%) RA 89 (24.7%) Osteoarthritis 43 (11.9%) Pigmented villonodular synovitis 28 (7.8%) Hemophilic arthropathy 23 (6.4%) Undifferentiated arthritis 22 (6.1%) Juvenile idiopathic arthritis 19 (5.3%) Other inflammatory arthritis 15 (4.2%) Recurrent joint effusion after surgery 9 (2.5%) Unknown 2 (0.5%) Concurrent medication nbDMARD 323 (89.7%) bDMARD 21 (5.8%) Unknown 16 (4.5%) Joint treated Knee 324 (82.7%) Ankle 24 (6.1%) Elbow 18 (4.6%) Wrist 13 (3.3%) Shoulder 9 (2.3%) Hip 4 (1.0%) Radiopharmaceutical [90Y]Y-citrate 327 (83.4%) [186Re]Re-sulfide 39 (10.0%) Unknown 26 (6.6%) Radiologic class of joint destruction 0 218 (55.6%) 1 36 (9.2%) 2 35 (8.9%) 3 36 (9.2%) Unknown 67 (17.1%) nbDMARD = nonbiologic disease-modifying antirheumatic drug; bDMARD = biologic disease-modifying antirheumatic drug.
Data are number followed by percentage in parentheses, except for age. Total patients = 360, and total joints = 392.
AE category All grades Severe Joint reaction Pain 9 (16.4%) 0 (0.0%) Inflammation 7 (12.7%) 3 (5.5%) Swelling 6 (10.9%) 0 (0.0%) Effusion 4 (7.3%) 1 (1.8%) Stiffness 1 (1.8%) 0 (0.0%) Septic arthritis 1 (1.8%) 1 (1.8%) Skin reaction Cutaneous necrosis 2 (0.6%) 1 (1.8%) Skin hematoma 2 (0.6%) 0 (0.0%) Systemic reaction Flushing 16 (4.4%) 0 (0.0%) Fever and chills 2 (0.6%) 0 (0.0%) Lymphadenopathy 2 (0.6%) 1 (1.8%) Nausea 1 (0.3%) 0 (0.0%) Palpitations 1 (0.3%) 0 (0.0%) Medication error 1 (0.3%) 1 (1.8%) Data are number followed by percentage in parentheses. Total AEs = 55.
Supplemental Data
Files in this Data Supplement:
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.